# US 2010/0166661 A1 · siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166661 A1
- Document ID: US20100166661A1
- Status: Published application
- Kind: A1
- Application number: 12/636,234
- Filed: 2009-12-11
- Published: 2010-07-01
- Earliest claimed: 2008-12-11
- Assignees: Xiangxue Group (Hong Kong) Company Limited
- Inventors: BOJIAN ZHENG; HONGYAN SUI; YONGPING LIN
- Web page: https://patentgrep.com/patent/US20100166661A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1131: {against viruses}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/10: in screening processes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.

## Claims

### Claim 1

An siRNA comprising the motif GGAGU or the reverse motif ACUCC.

### Claim 2 (depends on 1)

An siRNA according to claim 1, comprising a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, and SEQ ID NO: 37.

### Claim 3 (depends on 1)

A method of stimulating IL-6 production in a subject comprising administering to the subject an effective amount of an siRNA according to claim 1.

### Claim 4 (depends on 2)

A method of stimulating IL-6 production in a subject comprising administering to the subject an effective amount of an siRNA according to claim 2.

### Claim 5 (depends on 1)

A composition comprising an siRNA according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 2)

A composition comprising an siRNA according to claim 2 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 5)

A method of stimulating IL-6 production in a subject comprising administering to the subject an effective amount of a composition according to claim 5.

### Claim 8 (depends on 6)

A method of stimulating IL-6 production in a subject comprising administering to the subject an effective amount of a composition according to claim 6.

### Claim 9 (depends on 1)

A method of screening for potential anti-viral agents comprising:
obtaining an siRNA according to claim 1;
contacting cultured cells with said siRNA under conditions whereby the anti-viral properties of said siRNA can be observed; and
comparing any anti-viral properties of said siRNA with a control; whereby an siRNA exhibiting anti-viral properties greater than the control is determined to be a potential anti-viral agent.

### Claim 10 (depends on 9)

A method according to claim 9, wherein said control is a negative control or an untreated cell culture.

### Claim 11 (depends on 9)

A method according to claim 9, wherein said control is a positive control.

### Claim 12 (depends on 11)

A method according to claim 11, wherein said positive control is an siRNA comprising a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, and SEQ ID NO: 37.

### Claim 13 (depends on 1)

A method of screening for potential anti-viral agents comprising:
obtaining one siRNA according to claim 1;
administering said siRNA to an animal model and challenging said animal with virus under conditions whereby the anti-viral properties of said siRNA can be observed; and
determining whether said siRNA exhibits anti-viral properties in vivo.

### Claim 14 (depends on 13)

A method according to claim 13, further comprising comparing any anti-viral properties of said siRNA with a control whereby an siRNA exhibiting anti-viral properties greater than the control is determined to be a potential anti-viral agent.

### Claim 15 (depends on 14)

A method according to claim 14, wherein said control is a negative control or an untreated animal.

### Claim 16 (depends on 14)

A method according to claim 14, wherein said control is a positive control.

### Claim 17 (depends on 16)

A method according to claim 16, wherein said positive control is an siRNA comprising a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, and SEQ ID NO: 37.

### Claim 18 (depends on 9)

A method according to claim 9, wherein the anti-viral properties to be observed are anti-influenza A virus properties.

### Claim 19 (depends on 9)

A method according to claim 9, wherein the anti-viral properties to be observed are anti-H5N1 properties.

### Claim 20 (depends on 10)

A method according to claim 10, wherein the anti-viral properties to be observed are anti-influenza A virus properties.

### Claim 21 (depends on 10)

A method according to claim 10, wherein the anti-viral properties to be observed are anti-H5N1 properties.

### Claim 22 (depends on 11)

A method according to claim 11, wherein the anti-viral properties to be observed are anti-influenza A virus properties.

### Claim 23 (depends on 11)

A method according to claim 11, wherein the anti-viral properties to be observed are anti-H5N1 properties.

### Claim 24 (depends on 12)

A method according to claim 12, wherein the anti-viral properties to be observed are anti-influenza A virus properties.

### Claim 25 (depends on 12)

A method according to claim 12, wherein the anti-viral properties to be observed are anti-1-15N1 properties.

### Claim 26 (depends on 13)

A method according to claim 13, wherein the virus is an influenza A virus.

### Claim 27 (depends on 13)

A method according to claim 13, wherein the virus is H5N1.

### Claim 28 (depends on 14)

A method according to claim 14, wherein the virus is an influenza A virus.

### Claim 29 (depends on 14)

A method according to claim 14, wherein the virus is H5N1.

### Claim 30 (depends on 15)

A method according to claim 15, wherein the virus is an influenza A virus.

### Claim 31 (depends on 15)

A method according to claim 15, wherein the virus is H5N1.

### Claim 32 (depends on 16)

A method according to claim 16, wherein the virus is an influenza A virus.

### Claim 33 (depends on 16)

A method according to claim 16, wherein the virus is H5N1.

### Claim 34 (depends on 17)

A method according to claim 17, wherein the virus is an influenza A virus.

### Claim 35 (depends on 17)

A method according to claim 17, wherein the virus is H5N1.

### Claim 36 (depends on 1)

A method of stimulating β-defensin production in a subject comprising administering to the subject an effective amount of an siRNA according to claim 1.

### Claim 37 (depends on 2)

A method of stimulating β-defensin production in a subject comprising administering to the subject an effective amount of an siRNA according to claim 2.

### Claim 38 (depends on 5)

A method of stimulating β-defensin production in a subject comprising administering to the subject an effective amount of a composition according to claim 5.

### Claim 39 (depends on 6)

A method of stimulating β-defensin production in a subject comprising administering to the subject an effective amount of a composition according to claim 6.
